FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362696055> ?p ?o ?g. }

• W4362696055 endingPage "448" @default.
• W4362696055 startingPage "440" @default.
• W4362696055 abstract "Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma. Although outcomes to frontline therapy are encouraging, patients who are refractory to or in relapse after first-line therapy experience inferior outcomes. A significant proportion of patients treated with additional lines of cytotoxic chemotherapy ultimately succumb to their disease, as established in the SCHOLAR-1 study. Chimeric antigen receptor (CAR) T cell therapy is a novel approach to cancer management that reprograms a patient's own T cells to better target and eliminate cancer cells. It was initially approved by the US Food and Drug Administration for patients with relapsed/refractory (r/r) DLBCL as a third line of treatment. Based on recently published randomized data, CAR-T therapy (axicabtagene ciloleucel and lisocabtagene maraleucel) also has been approved as a second line of treatment for patients who are primary refractory or relapse within 12 months of first-line therapy. Despite the proven efficacy in treating r/r DLBCL with CD19-directed CAR-T therapy, several barriers may prevent eligible patients from receiving treatment. Barriers to CAR-T therapy include cost of therapy, patient hesitancy, required travel to academic treatment centers, nonreferrals, poor understanding of CAR-T therapy, lack of caregiver support, knowledge of available resources, and timely patient selection by referring oncologists. In this review, we provide an overview of the FDA-approved CD19-directed CAR-T cell therapies (tisagenlecleucel, axicabtagene ciloleucel, and lisocabtagene maraleucel) from pivotal clinical trials and supporting real-world evidence from retrospective studies. In both clinical trials and real-world settings, CAR-T therapy has been shown to be safe and efficacious for treating patients with r/r DLBCL: however, several barriers prevent eligible patients from accessing these therapies. Barriers to referrals for CAR-T therapy are described, along with recommendations to improve collaboration between community oncologists and physicians from CAR-T therapy treatment centers and subsequent long-term care of patients in community treatment centers." @default.
• W4362696055 created "2023-04-09" @default.
• W4362696055 creator A5007373641 @default.
• W4362696055 creator A5057975310 @default.
• W4362696055 creator A5067025516 @default.
• W4362696055 creator A5076075289 @default.
• W4362696055 creator A5090442154 @default.
• W4362696055 date "2023-07-01" @default.
• W4362696055 modified "2023-10-04" @default.
• W4362696055 title "Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma" @default.
• W4362696055 cites W1997353354 @default.
• W4362696055 cites W2018071905 @default.
• W4362696055 cites W2018269551 @default.
• W4362696055 cites W2028769138 @default.
• W4362696055 cites W2072646319 @default.
• W4362696055 cites W2172003817 @default.
• W4362696055 cites W2254037519 @default.
• W4362696055 cites W2427971560 @default.
• W4362696055 cites W2518731208 @default.
• W4362696055 cites W2759225097 @default.
• W4362696055 cites W2772481439 @default.
• W4362696055 cites W2809013389 @default.
• W4362696055 cites W2887810707 @default.
• W4362696055 cites W2893050608 @default.
• W4362696055 cites W2903225254 @default.
• W4362696055 cites W2905654445 @default.
• W4362696055 cites W2917035693 @default.
• W4362696055 cites W2917403768 @default.
• W4362696055 cites W2922398175 @default.
• W4362696055 cites W2944998775 @default.
• W4362696055 cites W2948047060 @default.
• W4362696055 cites W2964780371 @default.
• W4362696055 cites W2969216121 @default.
• W4362696055 cites W2990473850 @default.
• W4362696055 cites W2993256069 @default.
• W4362696055 cites W3011327279 @default.
• W4362696055 cites W3016878490 @default.
• W4362696055 cites W3024978145 @default.
• W4362696055 cites W3028800054 @default.
• W4362696055 cites W3036843041 @default.
• W4362696055 cites W3037830886 @default.
• W4362696055 cites W3038220775 @default.
• W4362696055 cites W3043369050 @default.
• W4362696055 cites W3082855561 @default.
• W4362696055 cites W3087742122 @default.
• W4362696055 cites W3095855647 @default.
• W4362696055 cites W3120123771 @default.
• W4362696055 cites W3133955595 @default.
• W4362696055 cites W3154903133 @default.
• W4362696055 cites W3192015208 @default.
• W4362696055 cites W3201013983 @default.
• W4362696055 cites W3211186978 @default.
• W4362696055 cites W3213715450 @default.
• W4362696055 cites W4200303223 @default.
• W4362696055 cites W4200414258 @default.
• W4362696055 cites W4213449399 @default.
• W4362696055 cites W4220660060 @default.
• W4362696055 cites W4223614330 @default.
• W4362696055 cites W4224046834 @default.
• W4362696055 cites W4226366844 @default.
• W4362696055 cites W4226405096 @default.
• W4362696055 cites W4255357812 @default.
• W4362696055 cites W4281391642 @default.
• W4362696055 cites W4281889185 @default.
• W4362696055 cites W4283023614 @default.
• W4362696055 cites W4283524047 @default.
• W4362696055 cites W4284897110 @default.
• W4362696055 cites W4285606063 @default.
• W4362696055 cites W4286449704 @default.
• W4362696055 cites W4289277826 @default.
• W4362696055 cites W4290725268 @default.
• W4362696055 cites W4290851731 @default.
• W4362696055 cites W4293125185 @default.
• W4362696055 cites W4296685812 @default.
• W4362696055 cites W4298149109 @default.
• W4362696055 cites W4385986623 @default.
• W4362696055 doi "https://doi.org/10.1016/j.jtct.2023.04.003" @default.
• W4362696055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37031747" @default.
• W4362696055 hasPublicationYear "2023" @default.
• W4362696055 type Work @default.
• W4362696055 citedByCount "4" @default.
• W4362696055 countsByYear W43626960552023 @default.
• W4362696055 crossrefType "journal-article" @default.
• W4362696055 hasAuthorship W4362696055A5007373641 @default.
• W4362696055 hasAuthorship W4362696055A5057975310 @default.
• W4362696055 hasAuthorship W4362696055A5067025516 @default.
• W4362696055 hasAuthorship W4362696055A5076075289 @default.
• W4362696055 hasAuthorship W4362696055A5090442154 @default.
• W4362696055 hasBestOaLocation W43626960551 @default.
• W4362696055 hasConcept C10882517 @default.
• W4362696055 hasConcept C121608353 @default.
• W4362696055 hasConcept C126322002 @default.
• W4362696055 hasConcept C143998085 @default.
• W4362696055 hasConcept C1491633281 @default.
• W4362696055 hasConcept C2776694085 @default.
• W4362696055 hasConcept C2777701055 @default.
• W4362696055 hasConcept C2778559949 @default.
• W4362696055 hasConcept C2779338263 @default.

• next